|
US3773919A
(en)
|
1969-10-23 |
1973-11-20 |
Du Pont |
Polylactide-drug mixtures
|
|
US4245051A
(en)
|
1978-03-30 |
1981-01-13 |
Rockefeller University |
Human serum plasminogen activator
|
|
IE52535B1
(en)
|
1981-02-16 |
1987-12-09 |
Ici Plc |
Continuous release pharmaceutical compositions
|
|
US4658830A
(en)
|
1984-08-08 |
1987-04-21 |
Survival Technology, Inc. |
Method and apparatus for initiating reperfusion treatment by an unattended individual undergoing heart attack symptoms
|
|
DE3515869A1
(de)
|
1985-05-03 |
1986-11-13 |
Bayer Ag, 5090 Leverkusen |
Verfahren zur herstellung optisch aktiver azolderivate
|
|
JPS62153224A
(ja)
|
1985-12-27 |
1987-07-08 |
Green Cross Corp:The |
プラスミノゲン製剤
|
|
GB8721951D0
(en)
|
1987-09-18 |
1987-10-28 |
Thrombosis Research Trust |
Organic compounds
|
|
JP2764264B2
(ja)
|
1987-10-01 |
1998-06-11 |
株式会社ミドリ十字 |
線溶活性増強剤
|
|
AT402367B
(de)
|
1990-10-11 |
1997-04-25 |
Immuno Ag |
Pharmazeutische zubereitung auf basis von lys-plasminogen
|
|
AU4661493A
(en)
*
|
1992-07-01 |
1994-01-31 |
Beth Israel Hospital Boston |
Enhancement of thrombolytic therapy with deglycosylated plasminogen
|
|
US5520912A
(en)
|
1993-07-02 |
1996-05-28 |
Immuno Aktiengesellschaft |
Prevention and treatment of ischemic events and reperfusion injury resulting therefrom using lys-plasminogen
|
|
DK125693D0
(https=)
|
1993-11-05 |
1993-11-05 |
Novo Nordisk As |
|
|
DE4411143C2
(de)
|
1994-03-30 |
1996-08-01 |
Immuno Ag |
Thrombosemittel
|
|
CA2226575C
(en)
|
1995-07-27 |
2011-10-18 |
Genentech, Inc. |
Stabile isotonic lyophilized protein formulation
|
|
EP1001985A1
(en)
|
1997-06-26 |
2000-05-24 |
Karolinska Innovations AB |
Kringle domains 1-5 of plasminogen, capable of modulating angiogenesis in vivo
|
|
US7317003B2
(en)
|
1998-09-04 |
2008-01-08 |
National University Of Singapore |
Small peptides having anti-angiogenic and endothelial cell inhibition activity
|
|
US6465424B1
(en)
|
1999-02-17 |
2002-10-15 |
Bristol-Myers Squibb Company |
Anti-angiogenic agent and method for inhibiting angiogenesis
|
|
WO2000049871A1
(en)
|
1999-02-24 |
2000-08-31 |
Henry Ford Health System |
An anti-angiogenic kringle protein and its mutants
|
|
US6899877B2
(en)
|
1999-03-09 |
2005-05-31 |
Minu, L.L.C. |
Process for generating plasmin in the vitreous of the eye and inducing separation of the posterior hyaloid from the retina
|
|
US6964764B2
(en)
|
1999-11-13 |
2005-11-15 |
Talecris Biotherapeutics, Inc. |
Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin
|
|
US7544500B2
(en)
|
1999-11-13 |
2009-06-09 |
Talecris Biotherapeutics, Inc. |
Process for the production of a reversibly inactive acidified plasmin composition
|
|
US20020159992A1
(en)
|
2000-09-29 |
2002-10-31 |
Jack Henkin |
Antiangiogenic polypeptides and methods for inhibiting angiogenesis
|
|
US20030054988A1
(en)
*
|
2000-11-02 |
2003-03-20 |
Weidong-Richard Ji |
Modified plasminogen related peptide fragments and their use as angiogenesis inhibitors
|
|
WO2003014145A2
(en)
|
2001-08-10 |
2003-02-20 |
Novartis Ag |
Peptides that bind to atherosclerotic lesions
|
|
US7067492B2
(en)
*
|
2001-09-06 |
2006-06-27 |
Omnio Ab |
Method of promoting healing of a tympanic membrane perforation
|
|
CN1408431A
(zh)
|
2001-09-21 |
2003-04-09 |
北京华兴生生物技术有限公司 |
治疗与新生血管生成相关疾病的基因工程药物
|
|
US7202066B2
(en)
|
2002-01-29 |
2007-04-10 |
Carrington Laboratories, Inc. |
Combination of a growth factor and a protease enzyme
|
|
AU2003210137A1
(en)
*
|
2002-02-06 |
2003-09-02 |
N-Zyme Biotec Gmbh |
Method for producing recombinant proteins in micro-organisms
|
|
DE10390418D2
(de)
*
|
2002-02-06 |
2005-01-13 |
N Zyme Biotec Gmbh |
Verfahren zur Herstellung von rekombinanten Proteinen in Mikroorganismen
|
|
US20030199464A1
(en)
|
2002-04-23 |
2003-10-23 |
Silviu Itescu |
Regeneration of endogenous myocardial tissue by induction of neovascularization
|
|
EP1509236A4
(en)
|
2002-05-13 |
2008-07-30 |
Children S Hospital Los Angele |
TREATMENT AND PREVENTION OF ABNORMAL SCALING IN KELOIDS AND OTHER SKIN OR INTERNAL WOUNDS OR LESIONS
|
|
BR0310100A
(pt)
|
2002-05-17 |
2007-04-27 |
Esperion Therapeutics Inc |
métodos para tratar, prevenir ou reduzir a lesão de reperfusão isquêmica em um tecido ou órgão, e para prevenir ou tratar de uma condição associada com a privação de oxigênio, seguida por suprimento de oxigênio aumentado a um tecido ou órgão em necessidade disto
|
|
CN101518533A
(zh)
|
2002-12-06 |
2009-09-02 |
法布罗根股份有限公司 |
脂肪调节
|
|
ATE430731T1
(de)
|
2002-12-10 |
2009-05-15 |
Wyeth Corp |
Substituierte indoloxoacetylaminoessigsäurederivate als inhibitoren des plasminogenaktivatorinhibitors-1 (pai-1)
|
|
CN1451746A
(zh)
|
2003-03-20 |
2003-10-29 |
广州市启源生物科技有限公司 |
人纤溶酶原Kringle 5缺失突变重组多肽
|
|
WO2005026127A1
(ja)
|
2003-09-11 |
2005-03-24 |
Institute Of Medicinal Molecular Design. Inc. |
プラスミノゲンアクチベータインヒビター－１阻害剤
|
|
US20080017694A1
(en)
|
2003-09-24 |
2008-01-24 |
Alexander Schnell |
Braze Alloy And The Use Of Said Braze Alloy
|
|
JP4740531B2
(ja)
|
2003-09-30 |
2011-08-03 |
雪印乳業株式会社 |
骨吸収抑制剤
|
|
CN102660564B
(zh)
|
2004-04-22 |
2013-05-08 |
泰勒克里斯生物治疗学公司 |
重组修饰的纤溶酶
|
|
US8357147B2
(en)
|
2005-08-17 |
2013-01-22 |
Spinal Restoration, Inc. |
Method for repairing intervertebral discs
|
|
FR2882654B1
(fr)
*
|
2005-03-01 |
2007-04-27 |
Servier Lab |
Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
|
|
WO2006095713A1
(ja)
|
2005-03-08 |
2006-09-14 |
Institute Of Medicinal Molecular Design. Inc. |
プラスミノゲンアクチベータインヒビター－１阻害剤
|
|
CA2602946A1
(en)
*
|
2005-03-22 |
2006-09-28 |
Medstar Health, Inc. |
Delivery systems and methods for diagnosing and treating cardiovascular diseases
|
|
US20060257391A1
(en)
|
2005-05-11 |
2006-11-16 |
Bausch & Lomb Incorporated |
Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions
|
|
US20090123582A1
(en)
|
2006-03-24 |
2009-05-14 |
Akiko Kuwahara |
Ameliorating Agent for Metabolic Syndrome
|
|
AU2007290881B2
(en)
|
2006-08-28 |
2013-03-07 |
Omnio Healer Ab |
Candidates against infection
|
|
US20100028321A1
(en)
|
2006-08-28 |
2010-02-04 |
Omnio Healer Ab |
Drug target for preventing and treating periodontal disease, improving healing of periodontal wounds and promoting oral health
|
|
WO2008051794A2
(en)
|
2006-10-20 |
2008-05-02 |
Dow Global Technologies Inc. |
Uses of water-soluble cellulose derivatives for preventing or treating metabolic syndrome
|
|
CN101219219B
(zh)
|
2007-01-10 |
2013-02-13 |
北京普罗吉生物科技发展有限公司 |
包含血管抑素或其片段的复合物、其制备方法及应用
|
|
CN101015686B
(zh)
|
2007-02-06 |
2010-05-19 |
中国人民解放军军事医学科学院基础医学研究所 |
一种溶栓药物增效剂及其制备方法
|
|
US20080200387A1
(en)
|
2007-02-15 |
2008-08-21 |
Hua-Lin Wu |
Anti-angiogenic protein, composition and use thereof
|
|
AR067446A1
(es)
|
2007-07-11 |
2009-10-14 |
Otsuka Pharma Co Ltd |
Un medicamento para tratar higado graso que comprende cilostazol
|
|
AT505574B1
(de)
*
|
2007-08-10 |
2009-09-15 |
Affiris Forschungs & Entwicklungs Gmbh |
Mimotope zur behandlung von atherosklerose
|
|
US20090239868A1
(en)
|
2007-10-23 |
2009-09-24 |
Institute Of Medical Molecular Design, Inc. |
Inhibitor of pai-1 production
|
|
CN101842093B
(zh)
|
2007-10-23 |
2012-08-22 |
株式会社医药分子设计研究所 |
Pai-1产生抑制剂
|
|
PL2220221T3
(pl)
*
|
2007-11-29 |
2015-07-31 |
Grifols Therapeutics Inc |
Rekombinacyjnie zmodyfikowana plazmina
|
|
CA2711878A1
(en)
|
2008-01-09 |
2009-07-16 |
Intrexon Corporation |
Therapeutic inhibitors of pai-1 function and methods of their use
|
|
US20090208448A1
(en)
|
2008-02-15 |
2009-08-20 |
Solomon Keith R |
Inhibition of angiogenesis
|
|
US20100209350A1
(en)
*
|
2008-12-30 |
2010-08-19 |
Andreas Pfuetzner |
Biomarkers for Adipose Tissue Activity
|
|
WO2010083570A1
(en)
|
2009-01-23 |
2010-07-29 |
The University Of Sydney |
Novel metabolic disease therapy
|
|
CA2757615C
(en)
*
|
2009-03-31 |
2018-07-17 |
Renascience Co., Ltd. |
Plasminogen activator inhibitor-1 inhibitor
|
|
EP2424561A2
(en)
|
2009-04-30 |
2012-03-07 |
Catherine Blondel |
Methods for treating ocular conditions
|
|
WO2011004011A1
(en)
|
2009-07-10 |
2011-01-13 |
Thrombogenics Nv |
Variants of plasminogen and plasmin
|
|
CN105031605A
(zh)
|
2009-08-12 |
2015-11-11 |
康奈尔大学 |
预防或治疗代谢综合症的方法
|
|
CN101628113B
(zh)
|
2009-08-18 |
2012-01-04 |
南京农业大学 |
蚯蚓纤溶酶抗肝纤维化的应用
|
|
CN101897925B
(zh)
|
2009-12-16 |
2015-04-29 |
成都百康医药工业药理毒理研究院 |
一种治疗代谢综合症的药物组合物
|
|
WO2011139974A2
(en)
|
2010-05-03 |
2011-11-10 |
Abbott Laboratories |
Anti-pai-1 antibodies and methods of use thereof
|
|
US9044458B2
(en)
*
|
2010-08-09 |
2015-06-02 |
The Johns Hopkins University |
Inhibition of tat activating regulatory DNA-binding protein 43
|
|
CN102121023B
(zh)
|
2010-12-22 |
2012-07-04 |
中山大学 |
突变型人纤溶酶原kringle5及其制备方法及应用
|
|
JP6085568B2
(ja)
|
2011-01-05 |
2017-02-22 |
スロンボジェニックス・ナムローゼ・フェンノートシャップＴｈｒｏｍｂｏＧｅｎｉｃｓ ＮＶ |
プラスミノーゲンおよびプラスミンの変異体
|
|
CN102154253A
(zh)
|
2011-01-06 |
2011-08-17 |
郑州大学 |
具有抑制血小板凝集功能的微小纤溶酶原突变体及其制备方法和用途
|
|
WO2012109097A1
(en)
*
|
2011-02-10 |
2012-08-16 |
Trustees Of Dartmouth College |
Methods for increasing plasmin activity and promoting plaque regression in the treatment of atherosclerosis
|
|
MX2013010076A
(es)
|
2011-03-03 |
2014-04-07 |
Tersus Pharmaceuticals Llc |
Composiciones y metodos que comprenden c16:1n7 palmitoleato.
|
|
CN102199587B
(zh)
|
2011-03-24 |
2013-06-19 |
广东药学院 |
人纤溶酶原功能性突变体及其制备方法和应用
|
|
MX2013011294A
(es)
|
2011-03-30 |
2014-10-06 |
Univ Texas |
Metodos y composiciones para dirigir celulas adiposas en mamiferos.
|
|
CN102188699A
(zh)
|
2011-05-06 |
2011-09-21 |
南京农业大学 |
一种治疗动脉粥样硬化的药物组合物及其制备方法和应用
|
|
US20120058537A1
(en)
|
2011-07-27 |
2012-03-08 |
Fereidoun Mahboudi |
Chimeric truncated and mutant variant of tissue plasminogen activator (t-pa) resistant to plasminogen activator inhibitor-1
|
|
US9644196B2
(en)
|
2011-08-12 |
2017-05-09 |
Thrombogenics Nv |
Plasminogen and plasmin variants
|
|
CN102532326B
(zh)
*
|
2011-11-18 |
2017-06-09 |
南京大学 |
一种肿瘤靶向的人纤溶酶原Kringle5变体及其应用
|
|
CN103656630B
(zh)
|
2012-09-11 |
2015-07-08 |
江苏仁寿药业有限公司 |
一种提纯动物药材中纤溶酶并制备成中药组合物的方法
|
|
DK2914575T3
(da)
|
2012-10-31 |
2021-01-18 |
Univ Michigan Regents |
Plasminogen-aktivator-1-inhibitorer og fremgangsmåder til anvendelse deraf
|
|
WO2014160275A2
(en)
|
2013-03-14 |
2014-10-02 |
Battell Memorial Institute |
Biomarkers for liver fibrosis
|
|
TWI689490B
(zh)
|
2013-03-15 |
2020-04-01 |
英商邊緣生物科技有限公司 |
用於治療纖維化之經取代之芳族化合物及相關方法
|
|
CN105008320A
(zh)
*
|
2013-03-20 |
2015-10-28 |
埃莱万斯可再生能源科学股份有限公司 |
烷基酯和羧酸的酸催化低聚
|
|
CN104274449A
(zh)
|
2013-07-11 |
2015-01-14 |
无锡信达医疗器械有限公司 |
治疗肥胖症的药物组合物
|
|
TW201734054A
(zh)
|
2013-08-13 |
2017-10-01 |
賽諾菲公司 |
胞漿素原活化素抑制劑-１（ｐａｉ-１）之抗體及其用途
|
|
TN2016000048A1
(en)
|
2013-08-13 |
2017-07-05 |
Sanofi Sa |
Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
|
|
WO2015026494A2
(en)
|
2013-08-20 |
2015-02-26 |
Trustees Of Dartmouth College |
Methods for treating tissue fibrosis
|
|
PY1577621A
(es)
|
2014-12-19 |
2017-10-02 |
Prometic Biotherapeutics Inc |
Composicion farmaceutica que comprende plasminogeno y uso para el mismo
|
|
TWI801331B
(zh)
|
2015-11-03 |
2023-05-11 |
美商波麥堤克生物治療股份有限公司 |
纖維蛋白溶酶原缺乏症之纖維蛋白溶酶原替代療法
|
|
WO2017101867A1
(zh)
|
2015-12-18 |
2017-06-22 |
深圳瑞健生命科学研究院有限公司 |
一种预防或治疗糖尿病性神经损伤及其相关病症的方法
|
|
WO2017101870A1
(zh)
|
2015-12-18 |
2017-06-22 |
深圳瑞健生命科学研究院有限公司 |
一种预防或治疗糖尿病性视网膜病变的方法
|
|
WO2017101869A1
(zh)
*
|
2015-12-18 |
2017-06-22 |
深圳瑞健生命科学研究院有限公司 |
一种预防和治疗肝组织损伤及其相关病症的方法
|
|
CA3008185C
(en)
|
2015-12-18 |
2024-01-16 |
Talengen International Limited |
Method for prevention or treatment of acute and chronic thrombosis
|
|
TWI725092B
(zh)
|
2015-12-18 |
2021-04-21 |
大陸商深圳瑞健生命科學硏究院有限公司 |
纖溶酶原在製備預防或治療糖尿病腎病或其相關病症之藥劑上的用途
|
|
TWI624268B
(zh)
*
|
2015-12-18 |
2018-05-21 |
Talengen Institute Of Life Sciences Co Ltd |
纖溶酶原在製備藥劑上的用途及包括纖溶酶原之藥劑
|
|
WO2018107688A1
(zh)
|
2016-12-15 |
2018-06-21 |
深圳瑞健生命科学研究院有限公司 |
一种预防和治疗脂肪肝的方法
|
|
US11207387B2
(en)
|
2016-12-15 |
2021-12-28 |
Talengen International Limited |
Method and drug for preventing and treating obesity
|
|
WO2018107707A1
(zh)
|
2016-12-15 |
2018-06-21 |
深圳瑞健生命科学研究院有限公司 |
一种改善心脏病变的方法
|
|
TWI868051B
(zh)
|
2017-06-23 |
2025-01-01 |
美商波麥堤克生物治療股份有限公司 |
與pai-1過表現相關之病狀的纖維蛋白溶酶原治療
|